Prasugrel: a novel platelet ADP P2Y12 receptor antagonist. A review on its mechanism of action and clinical development.

Abstract:

:Antiplatelet therapy is the cornerstone of treatment for patients who present with acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI). Clopidogrel, in combination with aspirin, is associated with improvement in long-term clinical outcomes in these patients and is currently the antiplatelet therapy of choice. However, a significant number of patients experience recurrent ischemic events, which have been in part attributed to variability in individual response profiles to currently recommended treatment regimens. The presence of variable degrees of responsiveness, thus inadequate platelet inhibition in some patients, underscores the need for novel agents with more potency and less variable platelet inhibitory effects. Prasugrel (CS-747; LY640315), a novel third-generation oral thienopyridine, is a specific, irreversible antagonist of the platelet adenosine diphosphate (ADP) P2Y(12) receptor. Pre-clinical and early phase clinical studies have shown prasugrel to be characterized by more potent antiplatelet effects, lower interindividual variability in platelet response, and faster onset of activity compared with clopidogrel. Recent findings from large-scale Phase III testing showed prasugrel to be more efficacious in preventing ischemic events in ACS patients undergoing PCI; however, this is achieved at the expense of an increased risk of bleeding. This article reviews the currently available data regarding the efficacy and safety of prasugrel.

authors

Angiolillo DJ,Suryadevara S,Capranzano P,Bass TA

doi

10.1517/14656566.9.16.2893

subject

Has Abstract

pub_date

2008-11-01 00:00:00

pages

2893-900

issue

16

eissn

1465-6566

issn

1744-7666

journal_volume

9

pub_type

杂志文章,评审
  • Clopidogrel in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention.

    abstract::Clopidogrel has become a mainstay in the management of acute coronary syndrome patients over the past decade, as well as an essential component of percutaneous coronary intervention (PCI) pharmacotherapy. Until recently, no prospective study has evaluated the effectiveness of clopidogrel in the setting of an ST-segmen...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.12.1669

    authors: Hamdalla H,Moliterno DJ

    更新日期:2006-08-01 00:00:00

  • Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012

    abstract:INTRODUCTION:Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system involving inflammation, chronic demyelination and axonal loss. MS affects more than 2 million people worldwide. AREAS COVERED:This article aims to summarize the findings from two pivotal 2-year, randomized, do...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章

    doi:10.1517/14656566.2013.826190

    authors: Havrdova E,Hutchinson M,Kurukulasuriya NC,Raghupathi K,Sweetser MT,Dawson KT,Gold R

    更新日期:2013-10-01 00:00:00

  • A review of olanzapine pamoate.

    abstract:INTRODUCTION:Olanzapine long-acting injection (OLAI), or olanzapine pamoate , is one of three second generation (SGA) antipsychotics now available in a long-acting formulation. OLAI is a microcrystalline salt of pamoic acid and olanzapine suspended in an aqueous solution that slowly dissociates into the separate compon...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656566.2012.686169

    authors: Chue P,Chue J

    更新日期:2012-08-01 00:00:00

  • Lapatinib: a tyrosine kinase inhibitor with a clinical role in breast cancer.

    abstract::Lapatinib is a dual (ErbB-1 and ErB-2) receptor tyrosine kinase inhibitor (TKI) that was recently approved by the FDA for the treatment of advanced breast cancer. It shows synergy with trastuzumab, and has demonstrated clinical activity in trastuzumab-resistant tumour. This paper reviews the drug development of lapati...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.13.2189

    authors: Mukherjee A,Dhadda AS,Shehata M,Chan S

    更新日期:2007-09-01 00:00:00

  • Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity.

    abstract::Migraine is a multifactorial and disabling syndrome often in comorbidity with psychiatric illnesses. Triptans are the first-line treatment in acute attacks and the most effective drugs in various types of migraine. Sumatriptan was the first medication of this group. Thanks to multiple types of formulations that greatl...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.2014.858120

    authors: Napoletano F,Lionetto L,Martelletti P

    更新日期:2014-02-01 00:00:00

  • New phosphodiesterase inhibitors in the treatment of erectile dysfunction.

    abstract::Sildenafil revolutionised the treatment of erectile dysfunction (ED) on its introduction in 1998. Not only is it effective, but is, perhaps even more importantly, an extremely acceptable manner in which to treat ED (i.e., oral pharmacotherapy), compared to the other treatments that were available at that time (e.g., i...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.11.2241

    authors: Anderson PC,Gommersall L,Hayne D,Arya M,Patel HR

    更新日期:2004-11-01 00:00:00

  • Pemetrexed for the treatment of non-small cell lung cancer.

    abstract:INTRODUCTION:Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. Although advanced NSCLC is still incurable, various anti-neoplastic agents have become available for the treatment of this disease. Pemetrexed , a multi-target folate antagonist, has improved the survival of non-squamous...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.802774

    authors: Genova C,Rijavec E,Truini A,Coco S,Sini C,Barletta G,Dal Bello MG,Alama A,Savarino G,Pronzato P,Boccardo F,Grossi F

    更新日期:2013-08-01 00:00:00

  • Recommendations for the management of migraine in paediatric patients.

    abstract::Migraine is a common and disabling condition in children and adolescents. The complexity of migraine on a pathogenetic and clinical level results from the interaction between biological, psychological and environmental factors. Appropriate management requires an individually tailored strategy giving due consideration ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.731

    authors: Balottin U,Termine C

    更新日期:2007-04-01 00:00:00

  • Therapeutic options for Acinetobacter baumannii infections.

    abstract::Acinetobacter baumannii is an important cause of nosocomial infections, mainly in patients in intensive care units. This microorganism, although with slight differences depending on the country, presents resistance to multiple antimicrobial agents, occasionally including resistance to colistin: hence, it can be consid...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.4.587

    authors: Vila J,Pachón J

    更新日期:2008-03-01 00:00:00

  • Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?

    abstract:INTRODUCTION:Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication. However, beyond its antiplatelet and vasodilator properties, cilostazol seems to have significant effects on atherogenic dyslipidemia. AREAS COVERED:The effec...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.557359

    authors: Rizzo M,Corrado E,Patti AM,Rini GB,Mikhailidis DP

    更新日期:2011-03-01 00:00:00

  • Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.

    abstract::Venous thromboembolism is a frequent, life-threatening, postoperative complication of hip-fracture and total-knee-replacement surgery. Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation. Low molecular weight heparins, such as enoxapa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 评论,杂志文章,评审

    doi:10.1517/14656566.3.4.455

    authors: Doggrell SA

    更新日期:2002-04-01 00:00:00

  • Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

    abstract:INTRODUCTION:Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1316374

    authors: Hardin C,Shum E,Singh AP,Perez-Soler R,Cheng H

    更新日期:2017-05-01 00:00:00

  • Pharmacotherapy of hypercholesterolaemia: statins in clinical practice.

    abstract::The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events and to review their mechanism of action based on in vitro and in vivo studies. The clinical outcome of 15 major clinical...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.4.683

    authors: Moghadasian MH,Mancini GB,Frohlich JJ

    更新日期:2000-05-01 00:00:00

  • Pharmacological management of Cronkhite-Canada syndrome.

    abstract::Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.3.385

    authors: Ward EM,Wolfsen HC

    更新日期:2003-03-01 00:00:00

  • Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC.

    abstract:INTRODUCTION:The epidermal growth factor receptor (EGFR) is mutated in 15% of adenocarcinomas of the lung. In addition, the anaplastic lymphoma kinase (ALK) is altered in 8% of adenocarcinomas of the lung. Treatment of EGFR mutant and ALK translocation-positive tumors in NSCLC with tyrosine kinase inhibitors (TKI) resu...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.971013

    authors: Somasundaram A,Socinski MA,Burns TF

    更新日期:2014-12-01 00:00:00

  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.860443

    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • Emerging paradigms in targeted treatments for Asian patients with NSCLC.

    abstract:INTRODUCTION:EGFR-targeted drugs have been successfully approved in many countries and have demonstrated higher efficacy and lower toxicity than chemotherapy in molecularly defined subgroups of patients. Significant advances in clinical trials and studies focusing on targeted therapies have rapidly developed in Asia. ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1040391

    authors: Ke EE,Zhou Q,Wu YL

    更新日期:2015-06-01 00:00:00

  • Neoadjuvant or adjuvant chemotherapy in early breast cancer?

    abstract:INTRODUCTION:The administration of chemotherapy before (neoadjuvant), rather than after surgery (adjuvant) in early breast cancer has been considered an optional strategy for patients with operable breast cancer. We reviewed this concept considering recent results in the field. AREAS COVERED:Herein, the authors cover ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1746273

    authors: Montemurro F,Nuzzolese I,Ponzone R

    更新日期:2020-06-01 00:00:00

  • Posaconazole: a new broad-spectrum antifungal agent.

    abstract::The rising incidence of invasive fungal infections and the emergence of broader fungal resistance have led to the need for novel antifungal agents. Posaconazole is a new member of the triazole class of antifungals. It is available as an oral suspension and has a favorable toxicity profile, has demonstrated clinical ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.8.1167

    authors: Kwon DS,Mylonakis E

    更新日期:2007-06-01 00:00:00

  • Treatment advances in non-Hodgkin's lymphoma.

    abstract::Non-Hodgkin's lymphomas (NHL) encompass a heterogeneous group of lymphoid malignancies with varying natural histories and prognoses. Recent classifications for NHL have defined distinct lymphoma entities based on morphology, immunophenotype, genetic features, clonal cell lineage and clinical features. These new, more ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.3.451

    authors: Tan BR,Bartlett NL

    更新日期:2000-03-01 00:00:00

  • Pharmacotherapy of obstructive sleep apnea.

    abstract:INTRODUCTION:Obstructive sleep apnea syndrome is a common public health problem in the general population. The important health-related consequences of obstructive sleep apnea include cardiovascular disorders, such as myocardial infarction and hypertension, stroke, sudden death and difficult blood sugar control related...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.666525

    authors: Lin CM,Huang YS,Guilleminault C

    更新日期:2012-04-01 00:00:00

  • Therapeutic options for HIV-associated lymphomas.

    abstract:IMPORTANCE OF THE FIELD:The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options. AREAS COVERED IN THIS REVIEW:Thi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2010.502528

    authors: Spina M,Gloghini A,Tirelli U,Carbone A

    更新日期:2010-10-01 00:00:00

  • The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.

    abstract:BACKGROUND:This study examined the effects of short-term administration of the sodium glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, on visceral fat area (VFA) in Japanese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS:In this randomized, crossover, controlled clinical trial, overweight patient...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1317748

    authors: Kato K,Suzuki K,Aoki C,Sagara M,Niitani T,Wakamatsu S,Yanagi K,Aso Y

    更新日期:2017-06-01 00:00:00

  • Treatment options for lysosomal storage disorders: developing insights.

    abstract:INTRODUCTION:Lysosomal storage disorders (LSDs) are clinically heterogeneous disorders that result primarily from lysosomal accumulation of macromolecules in various tissues. LSDs are always progressive, and often lead to severe symptoms and premature death. The identification of the underlying genetic and enzymatic de...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.729039

    authors: van Gelder CM,Vollebregt AA,Plug I,van der Ploeg AT,Reuser AJ

    更新日期:2012-11-01 00:00:00

  • Treating myoclonic epilepsy in children: state-of-the-art.

    abstract:INTRODUCTION:Myoclonic seizures can be observed in various clinical settings and different epileptic conditions, including some forms of both diopathic and symptomatic epilepsies. Relatively little has been written on treatment of myoclonic seizures. Some old antiepileptic drugs, such as valproate and some benzodiazepi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.800045

    authors: Striano P,Belcastro V

    更新日期:2013-07-01 00:00:00

  • Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.

    abstract::The recently published results of the sequential treatment of postmenopausal osteoporotic women with subcutaneous abaloparatide (80 µg/day) (ABL) for 18 months followed by 6 months of oral alendronate (70 mg/week) (ALN) support the administration of an anti-resorptive agent after completion of a treatment course with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2017.1418857

    authors: Reginster JY,Al Daghri N,Kaufman JM,Bruyère O

    更新日期:2018-02-01 00:00:00

  • Role of aprotinin in the management of patients during and after cardiac surgery.

    abstract::Management of patients undergoing cardiac surgery has evolved in recent years as more is understood about the physiological changes and responses that occur during and after cardiopulmonary bypass (CPB). In particular, our understanding of the mechanisms involved in haemostasis and in the inflammatory response to bypa...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.7.1353

    authors: Punjabi PP,Wyse RK,Taylor KM

    更新日期:2000-12-01 00:00:00

  • Hydrochlorothiazide: is it a wise choice?

    abstract:INTRODUCTION:Hydrochlorothiazide (HCTZ) has not been shown to reduce mortality or cardiovascular events when given as a single agent. In fact, HCTZ increased cardiovascular death and coronary artery disease (CAD) compared to placebo and usual care in 2 randomized trials, yet it is the most prescribed diuretic in the Un...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.670636

    authors: DiNicolantonio JJ

    更新日期:2012-04-01 00:00:00

  • Tamoxifen and the female reproductive tract.

    abstract::The use of tamoxifen among women with breast cancer or at high risk of the disease has greatly expanded over the past several decades. Tamoxifen has a complex effect on the female reproductive tract and several tamoxifen-associated changes have been described among tamoxifen users. These include endometrial thickening...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.9.1399

    authors: Eltabbakh GH,Mount SL

    更新日期:2001-09-01 00:00:00

  • Iontophoretic transdermal fentanyl for the management of acute perioperative pain in hospitalized patients.

    abstract:INTRODUCTION:Intravenous (I.V.) morphine administered through a patient-controlled system currently represents the gold standard treatment for moderate to severe acute postoperative pain. To fix the limitations showed by the available I.V. patient-controlled analgesia (PCA) systems that may restrict its use in the clin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1146684

    authors: Fanelli A,Sorella MC,Chelly JE

    更新日期:2016-01-01 00:00:00